Brought to you by 
Genentech, Celldex set up trial collaboration for atezolizumab and varlilumab combo
06 Oct 2021
Executive Summary
In a Phase I/II study that's slated to start some time this year, Genentech Inc.'s atezolizumab (MPDL3280A; RG7446; RO5541267) will be combined with Celldex Therapeutics Inc.'s varlilumab (CDX1127) to examine the combination's safety, tolerability, and preliminary efficacy in renal cell carcinoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech, Celldex set up trial collaboration for atezolizumab and varlilumab combo
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice